The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials

Author(s): Stavroula A. Paschou, Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos Oikonomou, Alexios S. Antonopoulos, Konstantinos Batzias, Vasiliki Tsigkou, Konstantinos Mourouzis, Andromachi Vryonidou, Nikolaos Tentolouris, Manolis Vavouranakis, Dimitrios Tousoulis

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 46 , 2020

Become EABM
Become Reviewer
Call for Editor

Abstract:

We systematically reviewed the literature regarding the impact of dipeptidyl peptidase-4 inhibitors (DPP-4i) on vascular function, including endothelial function and arterial stiffness, as predictors of atherosclerosis progression and cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). We searched PubMed in order to identify clinical trials that investigated the effect of DPP-4i on vascular function in patients with T2DM when compared with placebo. Although 168 articles were initially found, only 6 studies (total 324 patients) investigated the effect of DPP-4i in comparison with placebo, specifically linagliptin and sitagliptin, and satisfied the inclusion criteria. There are scarce data to indicate that linagliptin may enhance endothelial function and exert a slight beneficial effect on arterial wall properties. Sitagliptin seems to have a neutral effect on these variables. Further trials are needed to elucidate the topic. The standards of reporting were in accordance with the PRISMA guidelines.

Keywords: Type 2 diabetes mellitus, DPP-4 inhibitors, endothelial function, arterial stiffness, cardiovascular health, molecular cardiology.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 46
Year: 2020
Published on: 30 December, 2020
Page: [5980 - 5987]
Pages: 8
DOI: 10.2174/1381612826666200417153241
Price: $65

Article Metrics

PDF: 65